Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

Pannus, Pieter; Depickère, Stéphanie; Kemlin, Delphine; Georges, Daphnée; Houben, Sarah; Olislagers, Véronique; Waegemans, Alexandra; Craeye, Stéphane De; Francotte, Antoine; Chaumont, Félicie; Oostveldt, Celien Van; Heyndríckx, Leo; Míchiels, Johan; Willems, Elisabeth; Dhondt, Emilie; Krauchuk, Marharyta; Schmickler, Marie-Noëlle; Verbrugghe, Mathieu; Loon, Nele Van; Dierick, Katelijne; Matagne, André; Desombere, Isabelle; Ariën, Kevin K.; Marchant, Arnaud; Goossens, Maria E.

doi:10.1016/j.vaccine.2023.03.047

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One possible explanation is immunosenescence, the aging of the immune system, which may delay the production of specific antibodies against new antigens in older individuals 28 . However, it has been reported that the effect of age diminishes after the third vaccination 15 , 29 – 31 , which is also consistent with the results of this study. After the third vaccination, it has been demonstrated that there are sufficient virus-specific memory B cells even in the elderly, leading to rapid antibody production 29 .…”

Section: Discussionsupporting

confidence: 93%

“…However, it has been reported that the effect of age diminishes after the third vaccination 15 , 29 – 31 , which is also consistent with the results of this study. After the third vaccination, it has been demonstrated that there are sufficient virus-specific memory B cells even in the elderly, leading to rapid antibody production 29 .…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses

Matsuura,

Fukushima,

Nakagama

et al. 2024

Sci Rep

View full text Add to dashboard Cite

To evaluate the antibody response following the initial four doses of mRNA vaccines (BNT162b2 or mRNA-1273) in SARS-CoV-2-naïve healthy adults and investigate factors influencing antibody titer increases, this prospective cohort study was conducted in Japan from March 2021. The study included participants who received either the 1st and 2nd doses (n = 467), 3rd dose (n = 157), or 4th dose (n = 89). Blood samples were collected before and up to 6 months after each dose, and anti-receptor-binding domain antibody levels were measured. Multivariate analysis (usin multiple linear regression or linear mixed models) revealed several factors significantly associated with higher post-vaccination antibody levels, including mRNA-1273 vaccine (after the 1st and 2nd dose), male gender (after the 3rd and 4th doses), younger age (after the 1st and 2nd dose), non-smoking status (after the 2nd dose), non-use of immunosuppressive agents (after the 1st dose), higher pre-vaccination antibody titers (after the 2nd, 3rd, and 4th doses), and higher post-vaccination fever (after the 2nd and 4th doses). Furthermore, longer intervals since the last dose were significantly associated with higher antibody levels after the 3rd and 4th doses. These findings provide valuable insights for optimizing vaccination strategies.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses

Matsuura,

Fukushima,

Nakagama

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination

Sánchez-Simarro,

Fernández-Soto,

Grau

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The immune effector mechanisms involved in protecting against severe COVID-19 infection in elderly nursing home residents following vaccination or natural infection are not well understood. Here, we measured SARS-CoV-2 Spike (S)-directed functional antibody responses, including neutralizing antibodies (NtAb) and antibody Fc-mediated NK cell activity (degranulation and IFNγ production), against the Wuhan-Hu-1, BA.4/5 (for NtAb), and Omicron XBB.1.5 variants in elderly nursing home residents (n = 39; median age, 91 years) before and following a third (pre- and post-3D) and a fourth (pre- and post-4D) mRNA COVID-19 vaccine dose. Both 3D and 4D boosted NtAb levels against both (sub)variants. Likewise, 3D and 4D increased the ability of sera to trigger both LAMP1- and IFNγ-producing NK cells, in particular against XBB.1.5. In contrast to NtAb titres, the frequencies of LAMP1- and IFNγ-producing NK cells activated by antibodies binding to Wuhan-Hu-1 and Omicron XBB.1.5 S were comparable at all testing times. Stronger functional antibody responses were observed in vaccine-experienced participants compared to vaccine-naïve at some testing times. These findings can contribute to identifying a reliable correlate of protection in elderly nursing home residents against severe COVID-19 and inform future vaccine strategies in this population group.

show abstract

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

Cited by 2 publications

References 25 publications

Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses

Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses

Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination

Contact Info

Product

Resources

About